| 750718 |
CELLS |
A Novel Likely Pathogenic Variant in the BLOC1S5 Gene Associated with Hermansky-Pudlak Syndrome Type 11 and an Overview of Human BLOC-1 Deficiencies |
2021-10-01 |
10.3390/cells10102630 |
Boeckelmann Doris, Wolter Mira, Käsmann-Kellner Barbara, Koehler Udo, Schieber-Nakamura Lea, Zieger Barbara |
| 750717 |
CELLS |
Terc Gene Cluster Variants Predict Liver Telomere Length in Mice |
2021-10-01 |
10.3390/cells10102623 |
Zeid Dana, Mooney-Leber Sean, Seemiller Laurel R., Goldberg Lisa R., Gould Thomas J. |
| 750716 |
CELLS |
Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
2021-10-01 |
10.3390/cells10102609 |
Quitterer Ursula, AbdAlla Said |
| 750715 |
CELLS |
Nuclear Dynamics and Chromatin Structure: Implications for Pancreatic Cancer |
2021-10-01 |
10.3390/cells10102624 |
Flores Luis F., Tader Brooke R., Tolosa Ezequiel J., Sigafoos Ashley N., Marks David L., Fernandez-Zapico Martin E. |
| 750714 |
ONCOLOGY REPORTS |
Downregulation of matriptase suppresses the PAR‑2/PLCγ2/PKC‑mediated invasion and migration abilities of MCF‑7 breast cancer cells |
2021-10-01 |
10.3892/or.2021.8198 |
Kim Jeong-Mi, Park Jinny, Noh Eun-Mi, Song Hyun-Kyung, Kang Sang, Jung Sung, Kim Jong-Suk, Youn Hyun, Lee Young-Rae |
| 750713 |
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY |
Characteristics of obstructive sleep apnea syndrome in patients with partial laryngectomy |
2021-10-01 |
10.1002/lio2.527 |
Nguyen Duc Trung, Faron Patrick, Tran Tan Dai, Nguyen Thi Phi Linh, Gallet Patrice, Toussaint Bruno |
| 750712 |
CLINICAL LUNG CANCER |
Overall Survival and Safety With Pemetrexed/Platinum +/- Anti-VEGF Followed by Pemetrexed +/- Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of Four Randomized Studies |
2021-10-01 |
10.1016/j.cllc.2021.10.010 |
Garon Edward B., Peterson Patrick, Rizzo Maria Teresa, Kim Jong Seok |
| 750711 |
CLINICAL LUNG CANCER |
Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Tr |
2021-10-01 |
10.1016/j.cllc.2021.09.010 |
Heymach John V., Mitsudomi Tetsuya, Harpole David, Aperghis Mike, Jones Stephanie, Mann Helen, Fouad Tamer M., Reck Martin |
| 750710 |
CLINICAL LUNG CANCER |
The Effects of HER2 alterations in EGFR mutant non-small cell lung cancer |
2021-10-01 |
10.1016/j.cllc.2021.08.012 |
Nagasaka Dr. Misako, Singh Vijendra, Baca Yasmine, Sukari Ammar, Kim Chul, Mamdani Hirva, Spira Alexander I., Uprety Dipesh, Bepler Gerold, Kim Edward S., Raez Luis E., Pai Sachin Gopalkrishna, Ikpeazu Chukwuemeka, Oberley Matthew, Feldman Rebecca, Xiu Joanne, Korn W. Michael, Wozniak Antoinette J., Borghaei Hossein, Liu Stephen V. |
| 750709 |
CLINICAL LUNG CANCER |
Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer |
2021-10-01 |
10.1016/j.cllc.2021.10.001 |
Page Ray D., Drusbosky Leylah M., Dada Hiba, Raymond Victoria M., Daniel Davey B., Divers Stephen G., Reckamp Karen L., Villalona-Calero Miguel A., Dix Daniel, Odegaard Justin I., Lanman Richard B., Papadimitrakopoulou Vassiliki A., Leighl Natasha B. |
